The Role of Epitranscriptomics in Development and Disease (R01, R21 - Clinical Trial Not Allowed)

Funding Agency:
National Institutes of Health

The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications from the scientific community to support outstanding research in the area of epitranscriptomics, i.e., the chemical modifications of RNA.  Evidence is accumulating that RNA modifications regulate the function of both coding and noncoding RNAs, suggesting that these modifications are involved in both development, and in health and disease.  Yet the extent and types of these RNA modifications as well as their roles in particular biological processes remain either poorly understood or not known.  The goal of the FOA is to promote research into the role of RNA chemical modifications in the initiation and progression of various developmental processes and disease states and conditions relevant to the scientific mission of the participating ICs.

Although this funding opportunity uses the R01 grant mechanism, it runs in parallel with a program announcement of identical scientific scope, PAR-18-831, which uses the R21 grant mechanism.

Application Due Dates: November 7, 2018, June 3, 2019, March 3, 2020, November 7, 2020, June 3, 2021

PAR-18-830 Expiration Date June 4, 2021  

Agency Website

Amount Description

Application budgets should not exceed $499,999 direct costs per year. Within that limit, applications need to reflect the actual needs of the proposed project.

The scope of the proposed project should determine the project period. The maximum project period is 5 years. 

    Funding Type

    Grant

    Eligibility

    Faculty

    Category

    Engineering and Physical Sciences
    Environmental & Life Sciences
    Medical
    Medical - Basic Science
    Medical - Clinical Science

    External Deadline

    June 3, 2021